Janchor Partners
Established in 2009, Janchor Partners is a long‐term industrialist investor, partnering with companies that have superior business models, favorable growth prospects and the potential to be part of long‐term positive structural dynamics of Asian countries and economies. As a genuine thought partner with its investee companies, Janchor Partners helps to increase long‐term corporate value and builds strong long‐term relationships with investee companies. Janchor Partners’ mission as an Industrialist Investor is anchored by its purpose to have a lasting impact through deep relationships by building insight and trust. This virtuous cycle of impact, insight and trust can produce win-win-win holistic outcomes that create long-term sustained value. Janchor Partners’ ability to invest for the long‐term is strengthened by its investment partners, comprising high quality global institutional investors including family offices, university endowments, foundations and pension funds, who commit their capital to Janchor Partners for multi‐year periods.
FPL believes that consumption credit presents a very large opportunity in India and the credit card is the best product to offer consumption credit to India’s growing younger population. Card acceptance has trebled in the three years after demonetisation and every category is getting digitized. Like the overall growth in adoption of digital payments, the adoption of credit cards too has grown, both in terms of card issuance and spends. However, the experience of using a credit card has not evolved to serve the digitally savvy young millennials. FPL has created a proprietary full-stack technology platform to deliver a next-gen credit card experience to its customers. Customers can use an intuitive mobile app along with their credit cards to manage every aspect of their credit life cycle. FPL launched the OneScore app in July this year to help customers understand and manage their credit score and behavior in a simple and secure way.
Abbisko Therapeutics is a drug company dedicated to innovative drug research and development. The company is founded by a group of seasoned drug hunters with rich research and managerial experience in top pharmaceutical companies globally and in China.
InventisBio is a biotech company whose product pipeline includes small molecule drug candidates for targeted therapies in lung cancer, breast cancer and gout. The company is also actively developing drugs that can be combined with other immune-oncology targeted therapies, such as PD-1 antibody, for various cancer indications. The company is co-founded by Dr. Yaolin Wang and other scientists who have previously worked at Merck and Schering-Plough, leading various drug discovery projects in oncology, metabolic and infectious disease areas.
Everest Medicines is dedicated to its mission of developing and commercializing novel transformative pharmaceutical therapies for patients in the Emerging Market including Asia Pacific territories. We strive to be the partner of choice for innovative companies around the world with products that address critical unmet medical needs for patients in the Emerging Market and have a high probability of market approval. The Everest Medicines team has deep expertise and extensive track record of high quality clinical development, regulatory affairs, CMC, business development and operations both in Asia Pacific territories and with leading global pharmaceutical companies.
RemeGen, Ltd. ("RemeGen") is a biopharmaceutical company in China dedicated to fulfilling unmet medical needs for patients with life-threatening conditions. RemeGen's main focus is research and development, manufacturing and commercialization of novel biologics, most notably monoclonal antibodies (mAb) and antibody-drug conjugates (ADCs). Headquartered in Yantai, Shandong Province, China, RemeGen has labs/offices in Beijing and California.
Rongchang Pharmaceutical has grown into a modern pharmaceutical company enterprise integrating the r$d,production and sales of modern chinese medicine and biological drugs.
Alphamab Oncology is a clinical-stage biopharmaceutical company dedicated to the discovery, development manufacturing and commercialization of world-class innovative therapeutics for cancer treatment with multiple in-house proprietary platforms in bispecifics, protein engineering and antibody screening, Alphamab Oncology has built a robust pipeline in oncology/ immunology, and they are striving to develop next-generation or best-in-class medicines to address unmet medical needs globally.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.